Aerie pharmaceuticals reports second quarter 2020 financial results and provides business update

Aerie pharmaceuticals reports second quarter 2020 financial results and provides business update.q2 adjusted loss per share $0.83.q2 gaap loss per share $1.05.q2 earnings per share estimate $-0.80 -- refinitiv ibes data.positive phase 2 topline results for ar-1105 implant indicate up to six-month sustained release.ar-15512 trial for dry eye, comet-1, set to initiate this year.
AERI Ratings Summary
AERI Quant Ranking